Assenagon Asset Management S.A. Decreases Stock Holdings in Haemonetics Co. (NYSE:HAE)

Assenagon Asset Management S.A. reduced its holdings in shares of Haemonetics Co. (NYSE:HAE) by 75.2% in the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 15,223 shares of the medical instruments supplier’s stock after selling 46,211 shares during the period. Assenagon Asset Management S.A.’s holdings in Haemonetics were worth $1,224,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Quarry LP purchased a new stake in Haemonetics during the second quarter worth approximately $39,000. Covestor Ltd grew its stake in Haemonetics by 184.8% during the first quarter. Covestor Ltd now owns 675 shares of the medical instruments supplier’s stock worth $58,000 after buying an additional 438 shares during the period. Daiwa Securities Group Inc. purchased a new stake in Haemonetics during the second quarter worth approximately $82,000. Canada Pension Plan Investment Board purchased a new stake in Haemonetics during the second quarter worth approximately $83,000. Finally, EntryPoint Capital LLC purchased a new stake in Haemonetics during the first quarter worth approximately $86,000. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

Haemonetics Trading Up 0.4 %

HAE opened at $71.47 on Friday. The stock has a market capitalization of $3.66 billion, a PE ratio of 32.05, a P/E/G ratio of 1.13 and a beta of 0.30. The firm’s fifty day moving average price is $75.46 and its 200 day moving average price is $82.77. The company has a debt-to-equity ratio of 1.35, a current ratio of 3.76 and a quick ratio of 2.33. Haemonetics Co. has a 12-month low of $70.25 and a 12-month high of $97.97.

Haemonetics (NYSE:HAE) last posted its quarterly earnings results on Thursday, August 8th. The medical instruments supplier reported $1.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.03 by ($0.01). The company had revenue of $336.17 million during the quarter, compared to analyst estimates of $335.08 million. Haemonetics had a net margin of 8.61% and a return on equity of 21.86%. The company’s revenue was up 8.0% on a year-over-year basis. During the same period in the prior year, the company earned $1.05 earnings per share. As a group, research analysts expect that Haemonetics Co. will post 4.57 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on HAE shares. CL King started coverage on shares of Haemonetics in a research report on Friday, September 13th. They set a “buy” rating and a $116.00 target price on the stock. Bank of America started coverage on shares of Haemonetics in a research report on Wednesday, September 11th. They set a “neutral” rating and a $85.00 target price on the stock. Citigroup reduced their target price on shares of Haemonetics from $94.00 to $85.00 and set a “neutral” rating on the stock in a research report on Thursday, August 22nd. Barrington Research reissued an “outperform” rating and set a $108.00 target price on shares of Haemonetics in a research report on Monday, September 23rd. Finally, BTIG Research started coverage on shares of Haemonetics in a research report on Tuesday, September 10th. They set a “buy” rating and a $112.00 target price on the stock. Three research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $106.14.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.